| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2002 | Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction | Ding, E.; Hu, H.; Hodges, B. L.; Migone, F.; Serra, D.; Xu, F.; Chen, Y. T.; Amalfitano, A. | Mol Ther 5, 436-446 | | | |
| 2001 | Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice | Ding, E. Y.; Hodges, B. L.; Hu, H.; McVie-Wylie, A. J.; Serra, D.; Migone, F. K.; Pressley, D.; Chen, Y. T.; Amalfitano, A. | Hum Gene Ther 12, 955-965 | | | |
| 1999 | Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase | Amalfitano, A.; McVie-Wylie, A. J.; Hu, H.; Dawson, T. L.; Raben, N.; Plotz, P.; Chen, Y. T. | Proc Natl Acad Sci U S A 96, 8861-8866 | | | |
